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Abstract
Background and Objective Circadian rhythms may
influence the pharmacokinetics of drugs. This study aimed
to elucidate whether the pharmacokinetics of the orally
administered drug sunitinib are subject to circadian
variation.
Methods We performed studies in male FVB-mice aged
8–12 weeks, treated with single-dose sunitinib at six dos-
ing times. Plasma and tissue samples were obtained for
pharmacokinetic analysis and to monitor messenger RNA
(mRNA) expression of metabolizing enzymes and drug
transporters. A prospective randomized crossover study
was performed in which patients took sunitinib once daily
at 8 a.m., 1 p.m., and 6 p.m at three subsequent courses.
Patients were blindly randomized into two groups, which
determined the sequence of the sunitinib dosing time. The
primary endpoint in both studies was the difference in
plasma area under the concentration–time curve (AUC) of
sunitinib and its active metabolite SU12662 between dos-
ing times.
Results Sunitinib and SU12662 plasma AUC in mice
followed an*12-h rhythm as a function of administration
time (p B 0.04). The combined AUC from time zero to
10 h (AUC10) was 14–27 % higher when sunitinib was
administered at 4 a.m. and 4 p.m. than at 8 a.m. and 8 p.m.
Twenty-four-hour rhythms were seen in the mRNA levels
of drug transporters and metabolizing enzymes. In 12
patients, sunitinib trough concentrations (Ctrough) were
higher when the drug was taken at 1 p.m. or 6 p.m.
than when taken at 8 a.m. (Ctrough-1 p.m. 66.0 ng/mL;
Ctrough-6 p.m. 58.9 ng/mL; Ctrough-8 a.m. 50.7 ng/mL;
p = 0.006). The AUC was not significantly different
between dosing times.
Conclusions Our results indicate that sunitinib pharma-
cokinetics follow an *12-h rhythm in mice. In humans,
morning dosing resulted in lower Ctrough values, probably
resulting from differences in elimination. This can have
implications for therapeutic drug monitoring.
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Key Points
Sunitinib is known for its narrow therapeutic window
and wide inter-patient variability in drug exposure,
which in part may be explained by a within-patient
variability in drug exposure, possibly due to daily
variations in absorption, distribution, metabolism,
and excretion of sunitinib.
In this study, we showed that the area under the
concentration–time curve of sunitinib and its active
metabolite SU12662 follows a 12-h rhythm in mice.
Patients had lower trough concentrations (Ctrough) of
both sunitinib and SU12662 when the drug was
administered in the morning, rather than intake at
later times of the day.
This is particularly interesting, since therapeutic drug
monitoring (TDM) is currently being suggested as a
step forward in the individualization of sunitinib
treatment. In TDM, the drug dose may be increased
or decreased based on Ctrough values to aim for
improved survival. Therefore, it is crucial to take the
administration time into account to prevent
erroneous dose escalations or reductions.
1 Introduction
Sunitinib (Sutent; Pfizer Labs, Division of Pfizer Inc, New
York, NY, USA) is a multi-targeted tyrosine kinase inhib-
itor (TKI) that is registered for the treatment of advanced
clear cell renal cell carcinoma (RCC), imatinib-resistant or
intolerant gastrointestinal stromal tumors (GIST), and
pancreatic neuro-endocrine tumors (pNET) [1–5]. There is
a large inter-patient variability in plasma concentrations of
sunitinib, which may be due to patient non-compliance,
drug–drug interactions [cytochrome P450 (CYP) 3A4-
modulating drugs], and inter-patient variability in pharma-
cokinetics [6]. Besides inter-patient variability in drug
exposure, variability within a patient due to intra-patient
variations in pharmacokinetic processes may also exist.
After oral intake, sunitinib is absorbed from the gas-
trointestinal tract, resulting in peak plasma concentrations
6–12 h after administration [1]. Food has no significant
effect on the exposure to sunitinib [1, 7]. In the liver,
sunitinib is mainly metabolized by the CYP3A4 enzyme to
its primary active metabolite SU12662, which is further
converted by CYP3A4 into several inactive compounds.
Both sunitinib and SU12662 are eliminated from the body
via the bile in the feces through efflux transporters in the
liver, namely the adenosine triphosphate (ATP)-binding
cassette sub-family B member 1 (ABCB1) and sub-family
G member 2 (ABCG2) [8].
Enzymes and transporters involved in the pharmacoki-
netics of drugs, such as CYP3A4 and ABCB1, have time-
dependent variations in expression which may have a pro-
found effect on the exposure to several drugs [9, 10]. These
variations may change the efficacy and/or toxicity profile of
drugs. This was previously shown in patients treated with
tacrolimus, a drug frequently used to prevent organ rejec-
tion after transplantation, where morning administration
resulted in higher area under the concentration–time curve
(AUC) levels than evening administration [11].
Two previous studies have compared the toxicity levels
of patients treated with sunitinib in the morning with those
of patients treated with sunitinib in the evening. No dif-
ferences in toxicity levels between morning and evening
dosing of sunitinib were found in either study. Although the
authors concluded that it is safe to take the drug either in the
morning or at night, sunitinib pharmacokinetics were only
examined during morning sunitinib administration and
these studies were not designed to study the chrono-efficacy
and chrono-tolerance of sunitinib exposure [12, 13].
Several studies have shown an association between
higher exposure to sunitinib and improved survival [14,
15]. In order to improve the efficacy of sunitinib treatment,
we wanted to gain insight into possible time-dependent
changes in sunitinib pharmacokinetics, for which we
designed a translational study. The primary aim of this
study was to examine whether the administration time of
sunitinib influences its pharmacokinetics. We studied the
effect of administration time on pharmacokinetic parame-
ters of sunitinib by measuring sunitinib and its active
metabolite in plasma and organ tissue of mice as well as in
plasma of cancer patients treated with sunitinib mono-
therapy. As a secondary aim, we studied the daily variation
in the activity of sunitinib-metabolizing enzymes and
transporters in murine hepatocytes and bowel tissue and
through the midazolam clearance test in patients, which is a
well-known marker of CYP3A activity [16].
2 Methods
2.1 Mice
Seven groups of 18 male FVB mice 8–12 weeks of age
were used in this study. For logistic reasons, mice were
housed under normal and reversed 12 h light/12 h dark
cycles (lights on/off or off/on at 8 a.m. and 8 p.m.) for at
least 1 week before the start of the experiment. Mice were
fed a standard diet ad libitum. The mice were fasted from
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3 h before pharmaceutical treatment to 1 h after adminis-
tration. Water was available ad libitum throughout the
entire experiment. This study was approved by an inde-
pendent Animal Ethical Committee under protocol number
EMC139-12-19.
2.2 Study Protocol
Sunitinib was dissolved in acidified water with a maximum
pH of 6.0, at a concentration of 5 mg/mL. All mice were
administered a fixed single dose of 1.06 mg, which was
based on a dose of 42.4 mg/kg and a mean weight of mice
of 25 g. Every 4 h, one group consisting of 18 mice was
administered a single dose of sunitinib through gavage,
starting at 8 a.m.
At six different times after the administration of suni-
tinib (t = 1, 2, 3, 5, 10, and 20 h), three mice with an
identical sunitinib dosing time were administered isoflu-
rane as anesthetic followed by 1 mL blood withdrawal by
eye extraction and euthanasia by cervical dislocation.
Directly after euthanasia, one liver lobe and the small
bowel were removed. Blood from each single mouse was
separately processed to plasma. Both plasma and tissue
samples were snap-frozen in liquid nitrogen and stored at
-80 C until further analysis.
The seventh group of mice served as a control group and
was administered solvent. Mice in this group were sacri-
ficed at 4-h intervals. Blood and organs of the mice in this
group were collected and stored under the same conditions
as those of the treated mice. Quantitative real-time poly-
merase chain reaction (PCR) was applied to tissue samples
to reveal potential time-dependent changes in the circadian
expression of murine orthologs of genes encoding drug
transporters and metabolizing enzymes involved in suniti-
nib pharmacokinetics, using known core clock genes as a
control (see the Electronic Supplementary Material).
2.3 Patients
A prospective randomized crossover trial was performed in
patients treated with sunitinib at the Department of Medical
Oncology of the Erasmus MC-Cancer Institute, Rotterdam,
The Netherlands. Patients were allowed to participate in
the study at any time during sunitinib treatment, with both
4 weeks on/2 weeks off treatment and with continuous
dosing regimen. Patients could participate in the study if
(1) they were aged C18 years; (2) they had a histologically
or cytologically confirmed diagnosis of advanced RCC,
GIST, or pNET for which treatment consisted of sunitinib
monotherapy; (3) they were using any stable dose of sun-
itinib at study entry (defined as at least 2 weeks’ continu-
ous dosing without dose modifications); (4) hematologic,
renal, and liver functions were adequate; and (5) written
informed consent was given. Exclusion criteria consisted of
(1) pregnancy or breastfeeding; (2) medical unstable con-
dition requiring treatment; (3) symptomatic central nervous
system metastases or a history of a psychiatric disorder that
would prohibit the understanding and giving of informed
consent; (4) major surgery within 2 weeks before start of
the protocol; (5) use of CYP3A4-inhibiting or -inducing
drugs; (6) problematic blood withdrawal; and (7) a known
allergy to sunitinib and/or midazolam.
2.4 Study Protocol
Patients were randomized to start intake of sunitinib either
at 8 a.m. (group A) or 6 p.m. (group B) in the next treat-
ment course after inclusion. In the course thereafter, a
crossover was performed to 6 p.m. for group A and 8 a.m.
for group B. Accordingly, the sequence of the time of
dosing of sunitinib in group A was morning–evening and in
group B was evening–morning. During both courses,
patients were hospitalized for 24 h in the third or fourth
week of the treatment cycle, when steady-state plasma
concentrations were achieved [8]. Blood samples for
pharmacokinetic measurements were taken at timepoints
t = 0, 1, 2, 4, 6, 8, 12, and 24 h after oral sunitinib intake.
During both hospitalization days, patients were subjected
to a midazolam clearance test as a marker of hepatic CYP3A
activity 2 h after administration of sunitinib. Midazolam
(2.5 mg) was administered intravenously through slow
infusion, and blood withdrawals to determine the pharma-
cokinetics of midazolam and its metabolite 10-OH-midazo-
lam were taken at timepoints t = 0.5, 2, and 6 h after
administration, as previously described by Lee et al. [17].
After amendment of the study protocol, based on the
outcome of the animal experiments, a subset of patients
was asked to participate in the study for a third treatment
course in which sunitinib was taken at 1 p.m.
This study was approved by the local medical ethical
board (MEC2012-138), and registered at the Dutch trial
registry (http://www.trialregister.nl, number NTR3526).
According to the instructions stated in the Codes for Proper
Use and Proper Conduct in the Self-Regulatory Codes of
Conduct (http://www.federa.org), all samples for sunitinib
and midazolam pharmacokinetic assessment were coded
and anonymized. The analytical methods for sunitinib and
midazolam quantification are described in the Electronic
Supplementary Material. Parameters for sunitinib and
SU12662 pharmacokinetics were combined AUC, trough
concentrations (Ctrough), and clearance of sunitinib.
2.5 Statistics
For an 83 % probability that the study would detect a treat-
ment difference at a two-sided 0.05 significance level and a
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20 % truemean difference inAUC and/or clearance between
treatment times, 18 patients were required. This is based on
the assumption that the within-patient standard deviation of
the pharmacokinetic parameters is 0.2. Patients were con-
sidered eligible after completing pharmacokinetic blood
withdrawal during two treatment courses. To compare sun-
itinib pharmacokinetic parameters between morning, after-
noon, and evening dosing times, the Wilcoxon signed-rank
test was used. CircWave Batch (Dr. Roelof Hut, University
of Groningen, Groningen, The Netherlands) v5.0 with cos-
inor analysis was used for harmonic regression analysis of
circadian oscillation using a 24-h wave in the expression of
genes and a 12-h wave in the pharmacokinetics of sunitinib,
with forward linear harmonic regression using anF test. User
defined a was chosen at 0.05.
3 Results
3.1 Sunitinib Pharmacokinetics in Mice
A total of 108 mice were treated with a single dose of suni-
tinib at six different timepoints over 24 h. Cosinor analysis
of the AUC time zero to 10 h (AUC10) plot showed a clear
12-h rhythm in the exposure to sunitinib and SU12662
(p = 0.0342 and p = 0.0027, respectively; Fig. 1a) and the
combined exposure (p = 0.0174) as a function of adminis-
tration time. The combined AUC of sunitinib and SU12662
was 14–27 % higher when the drug was administered at
4 a.m. and 4 p.m., rather than at 8 a.m. and 8 p.m.
Figure 1b–e shows the AUCs of sunitinib and SU12662
for liver and three consecutive sections of the intestine,
corresponding with the duodenum, jejunum, and ileum,
respectively. As shown, oscillations also occur in the
accumulation of sunitinib and its metabolite in these tis-
sues. However, the 12-h rhythm was only statistically
significant for SU12662 accumulation in the duodenum
(p = 0.0179; Fig. 1c) but not for sunitinib or SU12662
accumulation in other tissues. Sunitinib and SU12662
concentrations in both plasma and tissue samples showed a
broad inter-mouse variability.
Quantitative real-time PCR on liver tissue samples taken
from mice in various stages of their circadian rhythm
revealed daily fluctuations with a 24-h period in the activity
of the clock genes Bmal1, Cryptochrome 1 (Cry1), Dbp,
Period 2 (Per2), and Rev-erba. This was confirmed by the
cosinor analysis (p B 0.0214), showing that the mice in a
normal and reversed light–dark cycle were properly
entrained at the time of the experiment (Electronic Sup-
plementary Material Fig. 1).
In the liver, cosinor analysis showed circadian fluctua-
tions in the messenger RNA (mRNA) levels of Abcb1a,
Abcb1b, and Cyp3a11 (p B 0.047), but not in the
expression of Abcg2 (p = 0.254; Electronic Supplemen-
tary Material Fig. 2A). In duodenum and jejunum, the
expression of Abcb1a, Abcg2, and Cyp3a11 followed a
circadian rhythm (p B 0.0162; Electronic Supplementary
Material Fig. 2B and 2C). In the ileum, only a circadian
variation in Abcb1a expression was seen (p\ 0.001;
Electronic Supplementary Material Fig. 2D). This impli-
cates circadian expression of the genes involved in the
uptake and metabolism of sunitinib as a cause for daily
variations in sunitinib pharmacokinetics. The peak activi-
ties, as judged by their mRNA expression levels, for these
genes were all at different times of the day.
3.2 Patient Demographics
Twenty-seven patients were included in this study, of whom
16 patients completed at least two courses with pharmaco-
kinetic bloodwithdrawals (groupA, n = 7; groupB, n = 9).
One patient was excluded from the study due to inability to
withdraw blood, and one patient retracted informed consent
before the end of the study protocol. Nine patients stopped
sunitinib treatment during the study due to toxicity or pro-
gressive disease. A subgroup of 12 patients had pharmaco-
kinetic measurements at three different times of the day
during three courses of sunitinib. All patients used sunitinib
as first-line anti-cancer treatment.
Group A and group B were comparable in sex, age,
number of courses within the study protocol, and amount of
dose reductions before and within the study protocol. Of
the 16 patients who completed at least two courses with
pharmacokinetic blood withdrawals, three patients under-
went dose reductions in between the study courses. Six
patients had already undergone dose reductions before the
start of the study protocol. There were no dose escalations
prior to or during the study protocol in any of the patients.
Demographic characteristics are presented in Table 1.
3.3 Sunitinib Pharmacokinetic Parameters
The mean AUC from time zero to the end of dosing period
(AUCs) in 16 patients was 1,599 ± 592 ngh/mL when
sunitinib was administered at 8 a.m. (AUC8 a.m.) and
1,444 ± 536 ngh/mL when sunitinib was administered at
6 p.m. (AUC6 p.m.). In the 12 patients who underwent
pharmacokinetic blood sampling during three courses, no
difference was seen in AUC1 p.m. when compared with
dosing times at 8 a.m. (p = 0.21) or 6 p.m. (p = 0.24), as
shown in Fig. 2. However, a relevant difference in com-
bined Ctrough values was seen between morning and even-
ing dosing (n = 16, Ctrough-8 a.m. 50.7 ± 17.6 ng/mL,
Ctrough-6 p.m. 58.9 ± 21.6 ng/mL; p = 0.006). This was
also seen when comparing morning dosing and dosing
at noon (n = 12, Ctrough-8 a.m. 56.0 ± 19.6 ng/mL;
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Ctrough-1 p.m. 66.0 ± 25.2 ng/mL; p = 0.003). The clear-
ance (CL) of sunitinib was not significantly different
between the three dosing times (CL8 a.m. 42.0 ± 14.7,
CL1 p.m. 40.2 ± 13.5, CL6 p.m. 39.8 ± 9.8 L/h; p C 0.5).
Patients in group A had slightly higher AUC8 a.m. than
patients in group B. For all other pharmacokinetic param-
eters, there were no significant differences between the
both treatment groups (Table 2).
Fig. 1 Daily variations in the
area under the concentration–
time curve (AUC) for sunitinib
(solid lines) and SU12662
(dotted lines) in plasma (a),
liver (b), duodenum (c),
jejunum (d), and ileum (e) of
FVB mice treated with a single
dose of sunitinib. The x axis
indicates the time of sunitinib
administration, the y axis
represents the mean AUC
corresponding to the six
consecutive administration
times. Gray areas indicate it
was dark in the cages of the
mice, white areas indicate it
was light. AUC0–10 area under
the concentration–time curve
from time zero to 10 h
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3.4 Midazolam Clearance Test
Three out of 16 patients did not undergo midazolam
clearance tests at both hospitalization days, due to patient
request. In the remaining 13 patients, there was no signif-
icant difference in the ratio between midazolam and 10-OH-
midazolam between the administration times 10 a.m. and
8 p.m. (mean difference in 10-OH-midazolam/midazolam
ratio = 0.0184; p = 0.256). Group A was not different
from group B in outcome of the 10-OH-midazolam/
midazolam ratio in the morning or in the evening
(Table 2).
4 Discussion
In this translational study, sunitinib pharmacokinetics in
mice showed daily variations depending on the time of
administration. Sunitinib and SU12662 AUCs follow a
similar oscillation pattern as a function of administration
time, with a 14–27 % higher combined plasma AUC when
sunitinib was administered at 4 a.m. or 4 p.m., which is in
the middle of the active or inactive phase of the mice
respectively, rather than at 8 a.m. or 8 p.m. Although a
recent study in rabbits revealed significant differences in
the exposure to sunitinib between dosing at 8 a.m. or
8 p.m., this was not seen in our study in mice [18].
Both the sunitinib and the SU12662 AUCs in plasma
follow a similar pattern in an apparent 12-h rhythm. The
oscillation pattern is probably due to circadian rhythms in
both Cyp3a11 enzyme activity and expression of the efflux
transporters Abcb1a, Abcb1b, and Abcg2. The 12-h rhythm
in sunitinib and SU12662 pharmacokinetics may be due to
counteracting activities of these drug transporters and
metabolizing enzyme, since we observed variation in
mRNA expression with peak concentrations at different
times of the day.
In the 16 patients treated with sunitinib, the plasma
AUC was equal at three dosing times, which is in contrast
to our pre-clinical results. Despite the equality in daily
exposure to sunitinib, the Ctrough values of sunitinib were
Table 1 Characteristics of the 27 individuals who participated in the
clinical study
Characteristic Cohort A Cohort B
No. of patients 13 (48.1) 14 (51.9)
No. of courses within study
0–1 6 (46.2) 5 (35.7)
2 7 (53.8) 9 (64.3)
3 5 (38.5) 7 (50.0)
Sex
Male 10 (76.9) 12 (85.7)
Female 3 (23.1) 2 (14.3)
Age (years) 63.1 (10.9) 61.3 (7.4)
WHO-PS
0–1 13 (100) 13 (92.9)
2 0 (0) 1 (7.1)
Tumor type
RCC 13 (100) 12 (85.7)
pNET 0 (0) 2 (14.3)
Dose reductions during study 2 (22.2) 1 (11.1)
Duration of sunitinib treatment (months) 16.7 (26.8) 19.3 (22.2)
Values are expressed as n (%), except for age and duration of treat-
ment, which are mean (SD)
pNET pancreatic neuro-endocrine tumor, RCC renal cell carcinoma,
SD standard deviation, WHO-PS World Health Organization Perfor-
mance Score
Fig. 2 24-h concentration
curves of sunitinib and
SU12662 (mean ± SD) for
patients treated with sunitinib at
8 a.m., 1 p.m., and 6 p.m
856 J. S. L. Kloth et al.
significantly lower when patients were administered suni-
tinib in the morning than with noon or evening dosing.
Ctrough values were sampled just before the intake of a new
dose of sunitinib. In this phase of the pharmacokinetic
process, metabolism and elimination are the most impor-
tant determinants of drug concentrations.
This study showed that the midazolam clearance test
in patients was similar at 10 a.m. and 8 p.m., suggesting
similarity in hepatic CYP3A activity between these
timepoints. Since CYP3A4 has a key role in sunitinib
metabolism [8], this suggests that sunitinib metabolism
was similar at morning and evening dosing. Based on the
midazolam clearance test, it can be assumed that
metabolism did not vary between these timepoints.
Therefore, it is hypothesised that the difference in suni-
tinib Ctrough values may be attributed to daily changes in
elimination.
The daily variation in sunitinib Ctrough values is relevant
for future research. For sunitinib and other TKIs, a
threshold concentration for efficacy is known [15]. Thera-
peutic drug monitoring (TDM) is currently being investi-
gated as a potential improvement of sunitinib therapy,
using Ctrough values of sunitinib and SU12662 as an indi-
cator for daily exposure. In these studies, dose levels of
sunitinib are increased if Ctrough values are below the
threshold. A recently published study revealed that it is
feasible to administer sunitinib based on Ctrough values,
with threshold concentrations between 50 and 100 ng/mL
[19]. Patients in our study had fewer fluctuations in the
daily sunitinib concentration when sunitinib was
administered at noon or in the evening. Therefore, the
chance of dropping below the threshold of 50 ng/mL,
where sunitinib is thought to be ineffective, is smaller
when the drug is administered at these times of the day,
although the daily exposure is the same. Patients dosed in
the morning may therefore potentially undergo erroneous
dose escalations and suffer from more toxicity [20].
Interestingly, the daily variation in sunitinib AUCs
observed in mice was not confirmed in patients. The dis-
crepancy between pre-clinical models and patients may be
due to various reasons. First, the pharmacokinetics of
sunitinib may be different between mice and humans due to
species specificity in the orthologous CYP enzymes and
drug transporters involved in the pharmacokinetics of
sunitinib. Second, the mice in this study only received a
single dose of sunitinib and therefore steady-state plasma
concentrations were not reached at the time of pharmaco-
kinetic sampling. This is in contrast with the patients in our
study who were administered sunitinib for at least 2 weeks
before pharmacokinetic sampling took place. A third
explanation can be that while mice were kept under strict
light/dark cycles resulting in synchronized behavior, the
circadian rhythm in the patients in this study may be dis-
turbed by lifestyle or during the hospital stay for pharma-
cokinetic sampling. Pharmacokinetic samples were taken
both during day times and during night hours, which
resulted in waking of the patient. Fourth, the mice in this
study were genetically homogeneous, while in the human
population there is genetic heterogeneity.
Of note, there were some limitations in the pre-clinical
study. Only one blood withdrawal for pharmacokinetic
determination was possible from each mouse. Therefore,
the AUC is calculated from sunitinib concentrations that
are measured in different mice, which showed a large inter-
individual difference in sunitinib and SU12662 concen-
trations. These large variations in pharmacokinetics may
have been due to several causes. For instance, sunitinib was
administered through gavage. Possibly, the solvent was
partially left in the gavage tube and it was not noticed
whether mice vomited after gavage. Also, mice ranged in
age from 8 to 12 weeks and therefore may differ in weight.
In addition, mice were fasted from 3 h before gavage until
1 h after oral gavage to make sure the stomachs of all mice
were empty at the time of sunitinib administration. How-
ever, this may have caused stress to the animals and may
have affected the phase of peripheral circadian rhythms,
although analysis of mRNA levels of the core clock genes
excluded the latter possibility.
This study was not designed to detect differences in
pharmacodynamics (efficacy of treatment and toxicity)
between different dosing times of sunitinib. Patients were
allowed to participate at any time during sunitinib treat-
ment, and there was a broad variation in the on-treatment
Table 2 Pharmacokinetic parameters in group A and group B
Pharmacokinetic
measurementa
Group A
[mean (SD)]
Group B
[mean (SD)]
p Value
AUC8 a.m. 1,832 (623) 1,314 (426) 0.048
AUC1 p.m. 1,965 (679) 1,572 (665) 0.340
AUC6 p.m. 1,711 (663) 1,274 (377) 0.092
Ctrough-8 a.m. 64.1 (22.6) 48.1 (16.4) 0.094
Ctrough-1 p.m. 76.3 (26.2) 58.6 (23.6) 0.249
Ctrough-6 p.m. 69.0 (27.8) 52.4 (15.4) 0.122
CL8 a.m. 35.1 (14.0) 45.5 (12.0) 0.145
CL1 p.m. 34.5 (16.5) 44.3 (25.4) 0.435
CL6 p.m. 36.0 (12.9) 42.7 (5.8) 0.235
10-OH-MD/MD10 a.m. 0.081 (0.014) 0.095 (0.027) 0.251
10-OH-MD/MD8 p.m. 0.087 (0.027) 0.121 (0.084) 0.311
Bold value indicates that the difference is statistically significant
10-OH-MD/MDx ratio between 10-OH-midazolam and midazolam at
time x, AUCx combined area under the concentration–time curve of
sunitinib and SU12662 at sunitinib dosing time x, Ctrough-x combined
trough concentration of sunitinib and SU12662 at sunitinib dosing
time x, CLx sunitinib clearance at sunitinib dosing time x
Units of AUC ngh/mL, Ctrough-x ng/mL, CL L/h
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time between patients. Six out of 16 (38 %) patients had
previously undergone dose reductions due to severe tox-
icity, and at the time of participation in the study these
patients were treated at a dose level with an acceptable
toxicity profile. Therefore, differences in toxicity levels
between dosing times were not an endpoint in this study.
However, previous studies have reported that toxicities
from sunitinib treatment are similar in morning and even-
ing dosing [12, 13].
5 Conclusion
Altogether, we conclude that daily variation in the phar-
macokinetics of sunitinib exists, most likely resulting from
differences in sunitinib elimination. Patient’s plasma sun-
itinib Ctrough values are higher when administered in the
afternoon or evening, and during these dosing times more
stable drug concentrations are achieved than when
administered in the morning. It is therefore advised that
sunitinib should be dosed in the afternoon or evening in
daily clinical practice, and if TDM is implemented in
clinical practice, the administration time of sunitinib
should be taken into account.
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